United Kingdom (UK) IVF (in-vitro fertilization) Market Research Report, 2029

Thanks to its innovative research, progressive regulations, and strong healthcare infrastructure, the UK has become a major player in the worldwide in vitro fertilisation (IVF) sector. Following the birth of Louise Brown in 1978—the first "test-tube baby" ever—the United Kingdom has remained at the forefront of the development of reproductive technology. Established in 1990, the Human Fertilisation and Embryology Authority (HFEA) is the regulating agency that ensures high standards of practice and patient care for all reproductive procedures and research involving human embryos. The United Kingdom's IVF industry has experienced significant growth due to rising rates of infertility, technological breakthroughs in medicine, and rising public awareness of fertility treatments. Due to causes including lifestyle modifications, postponed motherhood, and medical disorders, infertility has increased demand for assisted reproductive technologies (ART). Some IVF procedures are funded by the NHS, but eligibility requirements and the number of cycles covered differ by location, therefore many people turn to private clinics for their reproductive needs. The UK is known as a centre for reproductive medicine in part because of the large number of internationally recognised fertility clinics and research facilities located there. From standard IVF to more complex techniques including intracytoplasmic sperm injection (ICSI), preimplantation genetic diagnosis (PGD), and egg freezing, these clinics provide a wide range of services. The effectiveness and success rates of IVF procedures are still being driven by cutting-edge research, which includes the creation of new techniques and the enhancement of current regimens. The regulatory framework in the UK encourages moral behaviour and patient safety. Transparency is ensured by the HFEA rules, which give prospective parents comprehensive details about clinic performance, success rates, and available treatments. In addition to promoting public trust, this regulatory scrutiny stimulates innovation and ongoing industry advancement. Socioeconomic variables impacting the UK IVF market include shifting cultural views on family formation, growing acceptance of same-sex and single-parent households, and the place of women in the workforce. The demography of people seeking fertility treatments has expanded as a result of these factors, which has fueled market expansion. According to the research report "United Kingdom Infertility Treatment Market Research Report, 2029," published by Actual Market Research, the United Kingdom Infertility Treatment market is anticipated to grow at more than 7% CAGR from 2024 to 2029. The Human Fertilisation and Embryology Authority (HFEA) recently unveiled the world's first fertility data dashboard, marking a major milestone in the UK's IVF industry. This dashboard improves openness and helps patients make educated decisions by offering previously unheard-of access to vast data on IVF success rates, treatment options, and patient demographics going back to 1991 (The Independent, HFEA). In addition, there has been a noticeable increase in egg freezing cycles (HFEA) and a surge in IVF procedures, with 76,000 cycles carried out in 2021 compared to 70,000 in 2019. These advancements show how the field of fertility treatments in the UK is always evolving and improving.

What's Inside a Actual Market Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

In the context of in vitro fertilization (IVF) treatments in the United Kingdom, the terms "Fresh Non-donor IVF Cycle," "Frozen Non-donor IVF Cycle," "Frozen Donor IVF Cycle," and "Fresh Donor IVF Cycle" refer to different types of IVF procedures based on the source and state of the eggs used. The expectant mother's eggs are taken and fertilised with the partner's or donor's sperm in a new non-donor IVF round. Without being frozen, the resultant embryos are inserted into the mother's uterus. A treatment called ovarian stimulation is performed on a woman in order to induce multiple egg production. The eggs are gathered and fertilised in a lab after they reach maturity. After a few days of culture, one or more of the embryos are chosen to be transferred into the woman's uterus during her menstrual cycle. Using their own eggs and sperm, couples frequently use this technique. Unless using donated eggs or frozen embryos is necessary for medical reasons, this is frequently the initial course of action. In contrast, the embryos in a frozen non-donor IVF round are not transplanted right away. Rather, following fertilisation, the embryos made from the woman's eggs and her partner's (or donor sperm) sperm are frozen. When the woman's body is hormonally ready to receive the embryo, which might increase the likelihood of a healthy pregnancy, the transfer takes place in a later cycle. A frozen donor IVF cycle uses donated eggs that have been frozen. This is for individuals who use donor eggs. After the eggs are thawed and fertilised with either donor or the intended father's sperm, the resultant embryos are placed into the recipient's uterus. This method offers flexibility and can be especially helpful when it's difficult to synchronise the cycles of the donor and receiver. Last but not least, a fresh donor IVF cycle entails matching the recipient's and egg donor's menstrual periods. The recipient's partner's (or donor's) sperm is used to fertilise newly extracted eggs from the donor. Not freezing in between, the embryos are then transferred, soon after fertilisation, to the recipient's uterus. In the UK, the kind of cycle selected is determined by a number of criteria, such as medical history, donor availability, and the particular infertility issues that the individual or couple receiving treatment is dealing with. The Human Fertilisation and Embryology Authority (HFEA), the regulatory agency for the UK, keeps an eye on these processes to make sure they are conducted ethically and safely. Assisted reproductive technologies, such as donor egg IVF, IVF with ICSI (Intracytoplasmic Sperm Injection), and conventional IVF, are important tools for treating infertility and assisting individuals and couples in realising their goal of becoming parents in the United Kingdom. In a laboratory setting, eggs are fertilised with sperm outside of the body during conventional in vitro fertilisation. When there are no serious problems with male infertility and the quality and quantity of the woman's eggs are thought to be enough for fertilisation, this method is frequently employed. Conventional IVF involves taking several eggs out of the woman's ovaries, fertilising them with sperm in a petri dish, and then putting the developed embryos back into the woman's uterus. In a specialised type of IVF called ICSI, an egg is directly injected with a single sperm to aid in fertilisation. When there are problems with male fertility, such low sperm count or poor motility, which makes it hard for sperm to naturally fertilise an egg, this technique is frequently employed. The likelihood of successful fertilisation and embryo development is increased with IVF with ICSI, especially in situations when traditional IVF may not be successful. When a woman cannot generate viable eggs on her own, in vitro fertilisation (IVF) using donor eggs is used. This process involves retrieving healthy donor eggs, fertilising them with sperm (from the partner or another donor), and then transferring the resultant embryos into the recipient's uterus. For women who might have reduced ovarian reserve, genetic abnormalities, or other health issues compromising the quality of their eggs, this alternative offers hope. Other IVF methods, such as preimplantation genetic testing, frozen embryo transfer, and egg freezing for fertility preservation, are available in the UK in addition to these standard procedures. These choices address a wide range of unique situations and fertility issues, giving couples the freedom to experiment with different approaches to reaching their reproductive objectives. The UK offers a wide range of sturdy and diversified healthcare services for cryopreservation, fertility, surgery, and research organisations. Fertility clinics, which provide a variety of assisted reproductive technologies and fertility treatments, are essential in helping individuals and couples on their road towards parenting. These clinics use the most recent developments in medicine to treat a range of infertility problems while offering individualised treatment and support. The UK's hospitals and surgical centres are leaders in the provision of all-encompassing healthcare services, including gynaecological, obstetrical, and reproductive specialised surgery. These centres provide patients undergoing surgical operations with the best levels of care and safety thanks to their cutting-edge facilities and highly qualified medical staff. A vital component of the healthcare system, cryobanks act as depots for reproductive tissues, gametes, and embryos. In order to preserve the viability and integrity of biological materials that have been preserved, these facilities follow strict regulatory criteria. This makes it easier for individuals and couples to access family planning alternatives, reproductive treatments, and research. Reproductive medicine and fertility research centres provide major contributions to the advancement of scientific knowledge and technical breakthroughs in the field. These institutions advance reproductive health outcomes, genetic screening, and fertility therapies, eventually helping patients and society at large, via ground-breaking research projects and cooperative efforts with healthcare practitioners. Essentially, the UK's comprehensive approach to research, cryopreservation, surgery, and fertility highlights its dedication to meeting a range of healthcare demands while promoting innovation and quality in reproductive medicine and related fields.

Make this report your own

We're excited to discuss your needs and our solutions. Let's schedule a call.

Ask an Expert

Kripa Shah

Senior Analyst

? Considered in this report • Historic year: 2018 • Base year: 2023 • Estimated year: 2024 • Forecast year: 2029

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

Aspects covered in this report • IVF market Outlook with its value and forecast along with its segments • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation By cycle • Fresh Non-donor IVF Cycle • Frozen Non-donor IVF Cycle • Frozen donor IVF Cycle • Fresh donor IVF Cycle By Conventional IVF • Conventional IVF • IVF with ICSI (Instracytoplasmic Sperm Injection) • IVF With Donor Eggs • other By End user • Fertility Clinics • Hospital & Surgical Centers • Cryobanks • Research institute The approach of the report: This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources. Intended audience This report can be useful to industry consultants, manufacturers, suppliers, associations, and organizations related to the IVF industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.